DeepNewz, mobile.

People-sourced. AI-powered. Unbiased News.

Screenshot of DeepNewz app showing story detail view.

Screenshot of DeepNewz app showing story list view.

Search

For You

European Medicines Agency News

Footer

AI

AI Fundraising
AI Modeling
AI Products

Business

Automobile
Company Earnings
Economics
Law
Prediction Markets
Real Estate
Rumors
Stocks
VC

Crypto

Airdrops
Blockchains
CBDCs
DeFi
Hacks
Markets
Memecoin
Mining
NFT
Regulation

Culture

Anime
Celebrities
Crime
Education
Movies
Music
Obituary
TV
Video Games

Environment

Climate
Energy
Natural Disasters
Natural Resources
Sustainability

Politics

DOGE
Epstein Files
Executive Orders
Tariffs
US Domestic Policy
US Elections
US Foreign Policy
US Gov Appointments
US Judiciary
US Legislation
War

Science

Archeology
Bio
Health
Math
Pharma
Physics
Space

Sports

Boxing
Chess
Cricket
Golf
Hockey
MLB
NBA
NCAA
NFL
Olympics
PGA
Poker
Racing
Rugby
Soccer
Tennis
UFC

Tech

AR-VR
Fintech
Infosec
IoT
Metaverse
Policy
Robotics
Smart Home
Software
Startups
Wearables

United States

Arizona
Boston
California
Chicago
Colorado
Detroit
Florida
Georgia
Las Vegas
Los Angeles
New Jersey
New Mexico
New York
Ohio
Oregon
Philadelphia
San Francisco
Seattle
Texas
Utah
Washington DC

World

Terms of Service

WhatsApp YouTube X

© 2025 DeepNFTValue, Inc. All rights reserved.

Top stories

EMA Rejects Sarepta and Roche Duchenne Gene Therapy, Shares Slide 14%

EMA Rejects Sarepta and Roche Duchenne Gene Therapy, Shares Slide 14%

Authors

11

8 days ago

4D Molecular Therapeutics Shares Rise on 52- and 60-Week 4D-150 Data Showing 78% Injection Reduction, EMA Pathway; Genentech Susvimo Maintains Vision Over 5 Years

4D Molecular Therapeutics Shares Rise on 52- and 60-Week 4D-150 Data Showing 78% Injection Reduction, EMA Pathway; Genentech Susvimo Maintains Vision Over 5 Years

Authors

7

24 hours ago

FDA Approves New Dosing for Eli Lilly’s Kisunla to Reduce Brain Swelling; U.K. NHS Rejects Drug, EMA Recommends Approval; Leqembi Shows Four-Year Benefit

Authors

13

5 days ago

Lilly Alzheimer’s Drug Donanemab Wins EMA Panel Backing

Authors

6

8 days ago

Prediction markets for European Medicines Agency

Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?

Mar 8, 9:11 AMJan 1, 3:59 PM

15721

OptionProbability

Cancer treatment

Targeting viral infections (e.g., HIV)

Enhancing human physical abilities

Anti-aging therapies

65

53

34

33

[Metaculus] Will wild influenza B/Yamagata be declared eradicated before 2030?

Nov 9, 12:20 AMJan 2, 5:00 AM

24.9%chance

7117

OptionVotes

YES

NO

184

102

Latest stories

Latest stories

Aug 1, 2025
Aug 1, 2025
Stocks
Pharma
Business
4D Molecular Therapeutics Shares Rise on 52- and 60-Week 4D-150 Data Showing 78% Injection Reduction, EMA Pathway; Genentech Susvimo Maintains Vision Over 5 Years
Authors
7
24 hours ago
Jul 28, 2025
Jul 28, 2025
Europe
Britain
Pharma
FDA Approves New Dosing for Eli Lilly’s Kisunla to Reduce Brain Swelling; U.K. NHS Rejects Drug, EMA Recommends Approval; Leqembi Shows Four-Year Benefit
Authors
13
5 days ago
Jul 25, 2025
Jul 25, 2025
Stocks
Pharma
Business
EMA Rejects Sarepta and Roche Duchenne Gene Therapy, Shares Slide 14%
Authors
11
8 days ago
Jul 25, 2025
Jul 25, 2025
Europe
Pharma
Science
Lilly Alzheimer’s Drug Donanemab Wins EMA Panel Backing
Authors
6
8 days ago

Previous
Next

Join our channels

Get the latest stories live on any device.

WhatsApp
Top Stories
Join
Telegram
Top Stories
Join